

FY2024 Q3 Financial Results

Medical Data Vision Co., Ltd.
(Code: 3902)

November 11, 2024

1	Executive Summary	-----	3
2	FY2024 Q3 Financial Results	-----	4
3	FY2024 Consolidated Results Forecast Medium-term Management Plan	-----	14
4	Business progress	-----	17
5	Appendix	-----	30

Q3 results

FY consolidated results forecast and medium-term management plan

Measures to achieve the medium-term plan are progressing, no changes to the medium-term plan

- Delays in plans for 'ALPHA SALUS' and 'Karteco' impacting FY's financial results
- The FY2024 forecast is revised downward, however measures are progressing the foundation for sales growth to achieve the medium-term plan is being laid

Business progress

Status of services to achieve medium-term plan and future measures

- Substantial increase in personnel, building a structure for future growth is progressing as planned
- 'MDV Act' progressing as planned
- 'ALPHA SALUS' software issue repaired and resumed introduction
- 'Karteco' saw an increase in number of downloads thanks to TV commercials, 'Karteco' newly released for enterprises
- Data Utilization Services progressing to reach current FY sales target and for further growth in the next FY

FY2024 Q3 Financial Results



FY2024 Q3 results comparison (year-on-year)

Sales and Profit declined YoY

Sales : Mainly due to decrease of sales in Data Utilization Services

Profit : Decrease in profit due to lower sales. Increase in SG&A expenses due to execution of growth investments

(Millions of Yen)	Q3 (Q1-Q3)		
	FY2023 Q3 results	FY2024 Q3 results	YoY
Sales	4,487	4,125	-8.1%
Sales growth	+ 3.7%	-8.1%	—
Operating income	1,111	-140	—
Ordinary income	1,063	-229	—
Ordinary income ratio on sales	23.7%	-5.6%	—

Sales and Profit behind schedule


Sales : Delayed progress in Karteco, ALPHA SALUS, and Data Utilization Services

Profit : Lower profit due to decreased sales. Growth investments executed as planned, SG&A expenses generally in-line with plan

Image of this fiscal year's performance plan

Sales

Ordinary income



Concept of this FY's plan

- ① Sales growth driven by increased headcount in sales teams
- ② Expansion of sales in cloud-based services
- ③ Aggressive deployment of 'Karteco'

H1 : Increase/strengthen sales force, order-taking activities for cloud-based services, and wide-spread adoption of Karteco

H2 : Accumulation of recurring and non-recurring sales through expansion of cloud-services and sales growth by increasing Karteco users


Q3 Status

- 'MDV Act' development is progressing as planned
- 'ALPHA SALUS' software issue repaired and resumed introduction in October
- 'Karteco' had a large increase in number of downloads thanks to TV commercials, exceeding plan. Cat sensing function delayed into Q4 however with the launch of 'Karteco' for enterprises, progress being made in acquiring customers and prospective customers
- 'Data Utilization Services' delayed verse plan. Onset effect from increasing sales personnel gradual, however orders being received through sales collaboration with TXP Medical

‘MDV Act’ on track, ‘ALPHA SALUS’ and ‘Karteco’ delayed

Enhancements and development delays caused significant delays in business plans

Data network service
Image of this fiscal year’s performance plan



Concept of this FY’s plan

Sales growth through 3 services in focus this FY

- ①Expansion of ‘MDV Act’ sales
- ②Expansion of ‘ALPHA SALUS’ sales
- ③Aggressive deployment of ‘Karteco’

H1 : Order-taking activities for cloud-based services, wide-spread adoption of Karteco


H2 : Accumulation of recurring and non-recurring sales through expansion of cloud-services and sales growth by increasing Karteco users

Q3 Status

- ‘MDV Act’ development is progressing as planned
- ‘ALPHA SALUS’ software issue repaired and resumed introduction in October
- ‘Karteco’ had a large increase in number of downloads thanks to TV commercials, exceeding plan. Cat sensing function delayed into Q4 however with the launch of ‘Karteco’ for enterprises, progress being made in acquiring customers and prospective customers

Sales by Services of Focus (vs. Plan)

MDVAct




Concept of this FY's plan

- Steady build-up of recurring sales by increasing the number of contracted hospitals
- Sales growth by acquiring new contracted hospitals through release of new paid functions and cross-selling to existing customers

Q3 Status

- Focus being in acquiring new hospital contracts, hence increase in number of hospitals with paid contracts moderate (2024 Q2 674 hospitals→2024 Q3 683 hospitals)

ALPHA-SALUS




Concept of this FY's plan

- Target number of Medical checkup system installed facilities : 161 facilities (+61 facilities From FY2023)

Q3 Status

- Malfunction repair completed and introduction resumed in October, however difficult to achieve plan

カイルテコ 'karteco'



Concept of this FY's plan

- Number of downloads 780,000 downloads
- Sales 520mn yen

Q3 Status

- 'Karteco' had a large increase in number of downloads thanks to TV commercials, exceeding plan
- 'Karteco' for enterprises launched, progressing towards acquiring new customers and prospective customers
- Release of cat sensing function delayed into Q4

Data network service sales (year-on-year)

Sales decreased YoY due to partial cancellation of sales in Q2

Sales decrease in new business (subsidiary) due to merger with System Be Alpha

(Millions of Yen)	Q3(Q1-Q3)		
	FY2023 Q3 results	FY2024 Q3 results	YoY
Data network service	1,053	900	-14.6%
Recurring	655	646	-1.4%
Non-recurring	158	88	-44.4%
New businesses (subsidiaries)	239	161	-32.8%
Karteco	—	4	—

※System Be Alpha sales previously included in new business (subsidiaries), MDV acquiring System Be Alpha in July 2024, reclassified to recurring and non-recurring from 2024 Q3

‘MDV Act’ sales growth progressing as planned

‘Karteco’ downloads surpasses Q3 plan as TV commercials showing a positive effect


Indicators		FY2022 Results	FY2023 Results	FY2024 Q1 Results	FY2024 Q2 Results(Q1-Q2)	FY2024 Q3 Results(Q1-Q3)	FY2024 Targets
MDV Act sales growth rate		—	—	— ※	+ 196.8%	+ 106.6%	+ 78.4%
Number of installations of medical checkup systems		94	100	97	97	87	161
Karteco	Number of downloads	—	—	62,105	167,698	630,369	780,000
	Sales (Millions of Yen)	—	—	0	0	4	520

※ ‘MDV Act’ launches paid functions starting 2023 Q2

Results of sales alliance with TXP Medical beginning to show

To further strengthen cooperation and increase the number of receiving orders going into Q4 demand period

Data utilization service
Image of this fiscal year's performance plan



Concept of this FY's plan

- Maintain sales growth by strengthening sales force

H1 : Recruitment and development of sales personnel

H2 : Organic sales growth thanks to increased sales force

Q3 Status

- Winning orders through sales cooperation with TXP Medical
- Promptly strengthen new sales personnel to become immediate assets

Data utilization service sales (year-on-year)



Sales personnel have increased, but effect has been gradual

System is already in place, efforts being made to make sales force more effective going into Q4 demand period

(Millions of Yen)	Q3(Q1-Q3)		
	FY2023 Q3 results	FY2024 Q3 results	YoY
Data utilization service	3,030	2,836	-6.4%
Medical data survey analysis	2,373	2,157	-9.1%
MDV analyzer	657	678	+ 3.3%

FY2024 Q3 results:cost analysis

Substantial increase in staff, building a foundation for future growth progressing as planned

Headcount increase, upfront investment in 'MDV Act', 'ALPHA SALUS', 'Karteco'

(Millions of Yen)	【Consolidated】 FY2023 Q3 results	【Consolidated】 FY2024 Q3 results	YoY	Details
CoGS	328	351	+ 7.0%	• Increase in support costs (mainly costs for MDV Act paid functions, Karteco, and other cloud services) (+24M)
Personnel Costs	445	524	+ 17.8%	• Higher wage costs from salary increases, headcount rise, etc (+45M)
Hiring costs	9	41	+ 334.5%	• Increase in new graduate hire and training-related expenses (+12M) • Increase in mid-career hire related expenses (+15M)
Others	319	637	+ 99.2%	• Increase in advertising expenses (mainly Karteco) (+235M) • Increase in support costs (mainly AWS and other external service fees) (+29M)
R&D costs	24	39	+ 59.2%	• Increase in MDV Act development expenses (+11M)
non-operating expenses	28	30	+ 9.4%	• Investment loss on equity-method affiliate of SENSING Co., Ltd. (+2M)
Total costs※	1,121	1,543	+ 37.6%	
Employees	260	309	+ 18.8%	

※ The total of CoGS, SG&A and non operating expenses

FY2024 Consolidated Results Forecast Medium-term Management Plan

FY2024 Consolidated Results Forecast

Revised full-year consolidated earnings forecast

Mainly affected by delay verse plans in 'Karteco' and 'ALPHA SALUS',
issues have been resolved

Consolidated

(Millions of Yen)	FY2024 previous forecast	FY2024 revised forecast	Amount change	Percentage change	(Reference) FY2023 results
Sales	8,000	6,600	-1,400	-17.5%	6,419
Operating income	1,630	510	-1,120	-68.7%	1,770
Ordinary income	1,540	390	-1,150	-74.7%	1,700
Net income attributable to owners of parent	1,000	180	-820	-82.0%	979

No changes to medium-term management plan

Measures are progressing and the foundation for sales growth is being laid for achieving the medium-term management plan

FY2025
Sales

10 Billion
yen

FY2025
Ordinary
Income

2.5 Billion
yen
or more

Business progress



Status of services of focus and data utilization services, future measures

1

Cloud based hospital management improvement application
Expand sales of 'MDV Act' paid functions

2

Expand sales of cloud
based medical checkup systems ('ALPHA SALUS')

3

Promote widespread adoption of 'Karteco'

4

Growth of data utilization services


Cloud based hospital management improvement application

Expand sales of 'MDV Act' paid functions


Expanding sales of MDV Act is an important strategy for sales growth and new data collection

Strengthening capabilities of new sales personnel to become immediate assets and developing paid functionality are rapidly underway

Current situation



Secure data acquisition base through cloud migration




Increase sales personnel




Fiscal year sales forecast

350M

Future measures and 2025 sales plan




Cross-sell (Increase unit price per customer)



2025 sales plan

470M

Expand sales of 'MDV Act', improve data quality



Repair of software malfunction completed, constructing an efficient introduction installation system under way


Stronger sales force and installation system to boost sales and installations at once

Current situation

Software issue
repair
completed



Sales ·
installation
personnel
increase



Constructing
an efficient
installation
system



Fiscal year
sales forecast

39M

Future measures and 2025 sales plan

Receive early
orders by
prospects

MDV customer
base more than
1,200 hospitals

<Target>
Hospitals providing
medical checkups
among MDV customers
Approx. 60%

Plenty of proposal sources

ALPHA SALUS

+
カイルコ
'Karteco'

Competitive
advantage to
encourage medical
checkups

Effective
installations



2025 sales
plan

730M

3 Promote widespread adoption of 'Karteco'

Promoting TV commercials and transportation advertisements in metropolitan areas

Regardless of TV commercials having ended, downloads through searches have increased, leading to increased recognition

Mass media Advertising

TVCM



Mid-August ~
Area : Kanto, Kansai, Nagoya, Fukuoka, Hokkaido
Broadcasters : Fuji, Nippon Television Network

Traffic Advertising



Mid-August ~
Area : Kanto, Kansai, Nagoya, Fukuoka

Operational Advertising



Mid-August ~
Area : Nationwide

OTT(Over The Top) services


※ All screens are images



3 Promote widespread adoption of 'Karteco'

TV commercial effect leading to dramatic increase in downloads

Cumulative total exceeded Q3 plan, significant progress towards achieving KPI of 780,000 downloads this term



Solid line . . . Completed
Dotted line . . . Plan

3 Promote widespread adoption of 'Karteco'

Expansion of future prediction function, risk prediction diseases increased from 6 to 34 diseases

Leads to life-style change to stay healthy and prevent diseases, and encourages consultation post medical checkups

The image displays three screenshots of the Karteco app interface, illustrating its features for disease prediction and risk simulation.

Left Screenshot: Future Prediction (未来予測)

- Header: 未来予測 (Future Prediction)
- Text: 健診結果と設問回答を基に、あなたの未来「34疾患」を予測します。 (Based on health check results and questionnaire answers, we predict your future 34 diseases.)
- Buttons: 未来予測レポートを作成する (Create Future Prediction Report), 未来予測レポートを見る (View Future Prediction Report)
- Bottom Navigation: ホーム (Home), 一覧 (List), わたしの事 (About Me), お知らせ (Notice), 設定 (Settings)

Middle Screenshot: Future Prediction Report (未来予測レポート)

- Header: 未来予測 (Future Prediction)
- Section: 2024/9/30レポート (Report for 2024/9/30)
- Section: 未来予測レポートサマリ (Future Prediction Report Summary)
- Section: 健康リスクTOP3 (Top 3 Health Risks)

Rank	Disease	Risk Score
1	脳卒中 (Stroke)	12.3
2	胃十二指腸潰瘍 (Gastric/duodenal ulcer)	8.9
3	小腸大腸ポリープ (Small intestine/colon polyps)	6.4

- Section: 発症率TOP3 (Top 3 Incidence Rates)

Rank	Disease	Incidence Rate
1	小腸大腸ポリープ (Small intestine/colon polyps)	10.2倍
2	糖尿病 (Diabetes)	2.5倍
3	脂肪肝 (Fatty liver)	2.3倍

- Text: 病名をタップすると詳細が確認できます (Tap the disease name to check details)

Right Screenshot: Disease Details (疾患別詳細)

- Header: 疾患別詳細 (Disease Details)
- Section: 脳卒中 (Stroke)

Metric	Value
健康リスク (Health Risk)	12.3
疾患リスク (Disease Risk)	3.2%
疾患倍率 (Disease Multiplier)	2.5倍

- Section: リスクシミュレーター (Risk Simulator)

以下の項目を変化させることで、リスク値をシミュレーションできます。 (By changing the following items, you can simulate the risk value.)

Item	Current Value	Target Value
喫煙 (Smoking)	吸う (Smoke)	吸う (Smoke)
体重 (Weight)	62.1kg	62.1kg
血圧 (Blood Pressure)	85-140	85-140
糖質 (HbA1c) (Sugar)	6.1	6.1
脂質 (LDL-C) (Lipids)	138mg/dl	138mg/dl
肝機能 (γ-GTP) (Liver Function)	74U/l	74U/l

- Buttons: シミュレーションする (Simulate), 医療費情報 (Medical Cost Information)

Right Panel: Disease prevention · health maintenance

- Icons: Bed, Brain, Running person, Fork and knife

Bottom Panel: Encourage consultation

- Icons: Stethoscope, Hospital building


Price revision

Current 220 yen per month → 550 yen per month / 5,500 yen per year※New pricing plan

3 Promote widespread adoption of 'Karteco'

Release of 'Karteco workwell', a PHR system for companies

In addition to Sony Biz Networks, progress is being made in acquiring new customers and prospects



■ Overview

- Collaboration with Sony Biz Networks' cloud-based attendance management system "AKASHI"
- Propose a solution that objectively measures employee health conditions at the same time as managing attendance, predicting deterioration in health conditions at an early stage, and encourages remedial action

■ Features

- Combining attendance and vital sensing information, analyzes working habits and autonomic nerves, objectively measuring employees' mental state
- Using 'Emo Scan Approach', a new mental health approach consisting of 3 layers, 'objective measurement', 'subjective measurement', and 'result processing', help to create a tolerant and vibrant work environment

3 Promote widespread adoption of 'Karteco'

Accelerate dissemination with 'Karteco workwell'

'Karteco', a PHR system for consumers



Promotion of ALPHA
SALUS at installed
locations



PR

Mass advertising
Web advertising
etc.

Collaboration
with affinity
sites

Companies with high
affinity for medical
and health information

'Karteco workwell', a PHR system for companies



Corporations with
excellent health
management

Approx.20,000
companies ※1

Companies with
high affinity

Warehousing,
transportation,
construction etc.

AKASHI users



※1. As of March 11, 2024

※2. ITreview Category Report Attendance System (September 2020) / Midsize enterprise : 100~999 employees


※3. ITreview Category Report Attendance System (September 2021) / Midsize enterprise : 100~999 employees

3 Promote widespread adoption of 'Karteco'


Widespread promotion and usage of Karteco by approaching individuals and companies

Current situation

Increased recognition of 'Karteco'



Expanded functions of 'Karteco', a PHR system for consumers



Launch of 'Karteco workwell', a PHR system for companies



Fiscal year sales forecast

10M

FY Downloads forecast (Cumulative)

780,000

Future measures and 2025 sales plan

Promotion of widespread usage through individual and corporate approaches



「Karteco」



「Karteco workwell」

Continued PR implementation

- ① Promotion of ALPHA SALUS at installed locations
- ② PR
- ③ Collaboration with affinity sites

2025 sales plan


1,000M

2025 Downloads plan (Cumulative)

5,300,000

4 Growth of data utilization services


Promote measures to acquire sales in the current fiscal year and increase sales growth in the next fiscal year



Medium-term management plan

No changes to medium-term management plan

All efforts to be made to achieve plan



Sales growth and acquisition of new data through 3 focused services


Dramatic growth of Data Utilization Services through new data

Appendix



Q3 results by fiscal year, Q3 earnings by service

■ Q3 results by fiscal year




■ Q3 earnings by service

(Millions of Yen)	Data Network Service	Data Utilization Service	Other Service	All-company total
Sales	900	2,836	389	4,125
YoY	-14.6%	-6.4%	-3.4%	-8.1%
Gross income	225	2,507	321	3,055
YoY	-53.2%	-7.1%	+ 0.2%	-12.8%
Ordinary income	—	—	—	-229
YoY	—	—	—	—


Sales by quarter (breakdown by service)

(Millions of Yen)

- Other service
- Data network service
- Data utilization service




Data network service sales breakdown



※1 As of 2023 Q1, sales of Doctorbook and AIRBIOS previously classified as New business (subsidiaries), has been reclassified as 'Other services'

※2 As of 2024 Q3, sales of System Be Alpha previously classified as New business (subsidiaries), has been reclassified as 'Recurring', 'Non-recurring'

Data utilization service sales breakdown



*Owing to the absorption of MDV Trial on 1 January 2023, its sales, previously listed under New businesses (subsidiaries), are now included in medical data survey analysis.

IR Contents in English

<https://en.mdv.co.jp/investor-relations/>

Contacts

<https://en.mdv.co.jp/application/contactus/form.php?investor-relations-category2>

This document provides information intended solely to help readers' understanding of Medical Data Vision Co., Ltd. (MDV). Thus, MDV has no intention to solicit or encourage investment for securities or financial products mentioned in this document. Also, readers are advised that this document is not a disclosure document or statement of financial performance as required by Japan's Financial Instruments and Exchange Act, Act on Investment Trusts and Investment Corporations, related cabinet orders, cabinet office ordinances or rules, the rules governing companies listed on the Tokyo Stock Exchange, or any other applicable rules. This document contains forward-looking statements, including forecasts of financial position, results of operations, and business-related matters, as well as statements related to the plans and goals of the management of Medical Data Vision Co., Ltd. (MDV). There are a number of known and unknown risks and uncertainties that can cause MDV's actual results or performance to differ materially from any explicit or implicit forecasts contained herein. These forward-looking statements also rest on a number of assumptions with regard to MDV's present and future management strategies, as well as the political and economical environments in which MDV will conduct its future business operations. Although the information contained in this document is the best available at the time of publication, no assurances can be given regarding the accuracy, certainty, validity or fairness of this information. The content of this document can be modified or withdrawn without prior notice.



Medical Data Vision Co.,Ltd.

7 KandaMitoshirocho,Chiyoda-ku,Tokyo,Japan 101-0053

TEL.03-5283-6911 FAX.03-5283-6811